Skip to content
Peptide research

AOD-9604

Also known as Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A modified fragment of human growth hormone marketed for fat loss, said to boost fat breakdown without raising IGF-1 or blood sugar. The mechanism is solid, but the human case is weak: its pivotal trial failed to reach significance, and cartilage-repair claims stay speculative. The FDA has flagged impurity and immune-reaction concerns in compounded batches, and most supply is unregulated research-grade product. Not FDA-approved, banned in sport under WADA.

Read Full record

Studied uses & evidence

Studied uses(10)

  • Stimulates lipolysis (fat breakdown) in adipose tissue without affecting muscle mass

    Low

    Animal and cell studies show fat breakdown; human muscle mass effects remain unmeasured.

  • Inhibits lipogenesis (new fat formation/de novo fatty acid synthesis)

    Low

    Reduced fat formation seen in animal and cell studies only, not tested in humans.

  • Does not elevate IGF-1 levels, unlike full-length HGH

    High

    Confirmed across multiple human trials measuring IGF-1 directly, with no rise versus placebo.

Evidence limits

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

  • Children under 18

    Absolute

    No pediatric data.

Risk summary(11)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Failed to demonstrate statistically significant weight loss in pivotal Phase IIb clinical trial

    High
  • FDA has cited concerns about potential immunogenicity (immune reactions to the peptide)

    Moderate
  • FDA has cited concerns about peptide impurity profiles in compounded formulations

    Moderate
  • Limited long-term safety data beyond 24-week trial duration

    Moderate
  • Injection site irritation (subcutaneous administration)

    Low
  • Transient headache reported in some trial participants

    Low
  • Mild flu-like symptoms reported in some trial participants

    Theoretical
  • No data on safety during pregnancy or lactation

    Moderate
  • Quality control concerns with unregulated products sold online

    High
  • Potential for degradation and loss of efficacy if improperly stored (peptide stability concerns)

    Low
  • Prohibited in competitive sports — positive WADA test could result in sanctions

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.